<DOC>
	<DOCNO>NCT01579903</DOCNO>
	<brief_summary>This study conduct compare moroctocog alfa ( AF-CC ) act body administer 2 different dose presentation . The first current product vial prefilled diluent syrinx second new dual-chamber syringe dose presentation .</brief_summary>
	<brief_title>Relative Bioavailability Of Two Formulations Of Moroctocog Alfa ( AF-CC )</brief_title>
	<detailed_description>This study conduct order satisfy post-approval EMA commitment compare pharmacokinetics 2 dose presentation use study .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient least 18 year old severe moderately severe hemophilia A ( facto VIII concentration less equal 2 % ) . Negative test facto VIII inhibitor . If applicable , HIV hepatitis treatment stable time enrollment . Ability abstain use FVIII product 72 hour time . History positive test result factor VIII inhibitor . Presence bleed disorder addition Hemophilia A . Body weight less 50 kg . History alcoholism . Treatment investigational drug device within 30 day prior Screening visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>moroctocog alfa ( AF-CC )</keyword>
	<keyword>ReFacto AF</keyword>
	<keyword>dual-chamber syringe</keyword>
	<keyword>bioavailability</keyword>
</DOC>